Postoperative Ileus Market Size was USD 3,700 million in 2024

• The postoperative ileus market size was found to be USD 3.7 billion in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan] in 2024.
• The United States accounted for the largest postoperative ileus treatment market size, approximately 95% of the total market size in the 7MM in 2024, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• In 2024, incident cases of postoperative ileus accounted for approximately 379,500 cases in the United States.
• Leading postoperative ileus companies developing emerging therapies, such as Orexa BV, Tsumura USA, and others, are developing new therapy for postoperative ileus that can be available in the postoperative ileus market in the coming years. 
• The promising postoperative ileus therapies in clinical trials include ORE-001, TU-100, and others.
• As per DelveInsight's analysis, by 2034, among the therapies, the highest revenue is expected to be generated by anti-emetic in the 7MM.

DelveInsight's Postoperative Ileus Market Insights report includes a comprehensive understanding of current treatment practices, postoperative ileus emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). 

Key Factors Driving the Growth of the Postoperative Ileus Market 

High Clinical and Economic Burden of Postoperative Ileus

Postoperative ileus substantially increases length of stay, readmissions and per-patient hospital costs after abdominal and colorectal surgery, creating a strong financial incentive for hospitals to adopt therapies and pathways that shorten recovery.

Rising Volume of Surgeries and Higher-risk Patient Populations

Global increases in elective and emergency abdominal surgeries, driven by aging populations, rising cancer surgery volumes and expanding access to surgical care, expand the pool of patients at risk for POI and therefore the addressable market.

Launch of Emerging Postoperative Ileus Therapies

The postoperative ileus pipeline remains limited, with only a few mid-stage candidates such as ORE-001 (lidocaine) and TU-100 (Daikenchuto/TJ-100) in Phase II trials, emphasizing slow progress and a constrained innovation landscape.

Discover the postoperative ileus new treatment @ New Treatments for Postoperative Ileus

Postoperative Ileus Market Analysis

The management of postoperative ileus has seen little to no significant innovation over the past two decades. Historically, alvimopan (ENTEREG), a peripherally acting µ-opioid receptor antagonist (PAMORA), was the only FDA-approved treatment designed to accelerate gastrointestinal recovery after bowel resection. However, with the discontinuation of the branded product, current care now depends on generic medications and standard interventions. 

Existing treatments include prokinetic agents such as metoclopramide, which have restricted use due to adverse effects; NSAIDs and opioids; centrally acting opioid antagonists like naloxone, which are constrained by their potential to reverse analgesia; and peripheral opioid antagonists (PAMORAs) like alvimopan and methylnaltrexone, which target opioid effects in the gut, though alvimopan's proven efficacy is tempered by limited accessibility. Antiemetics manage nausea without resolving ileus, while laxatives offer only general symptomatic relief. Intravenous lidocaine can reduce opioid dependence and may serve as an adjunct to promote bowel recovery.

With no active branded therapies available, the postoperative ileus treatment landscape remains narrow but focused on addressing key underlying mechanisms such as impaired gastrointestinal motility and opioid-induced dysfunction. Notably, two Phase II candidates, ORE-001 (Orexa BV) and TU-100 (Tsumura), are progressing through development, with the goal of improving symptom control and overall disease management across the leading markets.

To know more about postoperative ileus treatment options, visit @ Approved Postoperative Ileus Drugs

Postoperative Ileus Competitive Landscape

Novel therapies like ORE-001 (Orexa BV), TU-100 (Tsumura USA), and others are currently under development to expand treatment choices. 

Orexa BV's ORE-001 is an oral formulation of lidocaine, aimed at enhancing appetite and supporting recovery in conditions like postoperative ileus, anorexia, and malnutrition among elderly patients. The drug is currently being tested in a Phase II clinical trial (NCT05923086) to assess its effectiveness in preventing postoperative ileus.

Tsumura's TU-100, a traditional Japanese herbal medicine, is under active investigation for its potential to aid recovery from postoperative ileus following abdominal surgery. It promotes intestinal motility through neural pathways by enhancing acetylcholine release via serotonergic receptor activation, while also exerting anti-inflammatory effects by reducing neutrophil and macrophage infiltration and improving intestinal blood flow.

The anticipated launch of these emerging therapies are poised to transform the postoperative ileus market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the postoperative ileus market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about therapy for postoperative ileus @ Postoperative Ileus Clinical Trials 

What is Postoperative Ileus?

Postoperative ileus, also known as Postoperative Gastrointestinal Dysfunction (POGD) or paralytic ileus, is a temporary disruption of normal gastrointestinal motility that frequently occurs after surgery, especially abdominal procedures. It is characterized by abdominal bloating and an inability to tolerate oral intake due to reduced gastrointestinal movement in the absence of any mechanical blockage. The condition often involves opportunistic fungal pathogens, which are normally harmless components of the environment or human flora but can become pathogenic when the host's immune defenses are compromised. The most common triggers include abdominal or pelvic surgeries and the administration of opioid painkillers or anesthesia.

Postoperative Ileus Epidemiology Segmentation

The postoperative ileus epidemiology section provides insights into the historical and current postoperative ileus patient pool and forecasted trends for the leading markets. Gastrointestinal/Abdominal Procedures accounted for approximately 5.68 million cases in 2024, representing a higher number than non-abdominal procedures in the at-risk population for postoperative ileus.

The postoperative ileus market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

• Total Gastrointestinal/Abdominal Procedures (at-risk population for postoperative Ileus)
• Total Incident Cases of Postoperative Ileus 
• Severity-specific Cases of Postoperative Ileus 
• Postoperative Ileus Prevention and Treatment Eligible Patient Population

Scope of the Postoperative Ileus  Market Report

• Therapeutic Assessment: Postoperative Ileus current marketed and emerging therapies
• Postoperative Ileus Market Dynamics: Key Market Forecast Assumptions of Emerging Postoperative Ileus Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Postoperative Ileus Market Access and Reimbursement

Download the report to understand which factors are driving postoperative ileus therapeutics market trends @ Postoperative Ileus Market Trends